When multiple myeloma relapses

Patients with relapsed multiple myeloma live longer on Kyprolis®* than on bortezomib*1

Kd superior overall survival

Kyprolis®* demonstrated superiority in efficacy by extending the median overall survival by 7.6 months vs bortezomib thereby reducing the risk of death by 21%.*1

Adapted from PR Newswire, 2017.2

The overall survival difference was consistent regardless of prior bortezomib therapy or number of prior therapies.1

Please read the SmPC for full comprehensive safety information

References

  1. Dimopoulos MA, et al. Abstract presented at the 16th International Myeloma Workshop; March 1–4, 2017; New Delhi, India.
  2. PR Newswire. Amgen presents overall survival data from KYPROLIS® (carfilzomib) phase 3 ENDEAVOR trial at 16th International Myeloma Workshop, available at: http://www.prnewswire.com/news-releases/amgen-presents-overall-survival-data-from-kyprolis-carfilzomib-phase-3-endeavor-trial-at-16th-international-myeloma-workshop-300417521.html, last accessed March 2017.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis